All News

My relationship with my body has changed over the years, especially during and after breast cancer. Now, I have accepted the way I look.

Patients with high-risk early-stage non-small cell lung cancer who underwent surgery reported similar quality of life outcomes as those who had radiation.

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

I hope my poem — which outlines my experience being diagnosed with colon cancer — brings light to someone’s day.

Jill May, B.S.N., RN, OCN, shows her commitment to her patients and their caregivers through acts of kindness and compassion — especially during tough times.

One night, I had a dream that I played chess with Death and well, I won.

Dayna Hardee, RN, encourages patients, letting them know that someone has their back, someone is praying for them and someone is responding when they have a need.

Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.

When it comes to high blood sugar, cancer and diabetes can create a “vicious cycle,” as one expert explained.

I use affirmation as a technique to turn my negative thoughts about colon cancer into positive ones. Now, I see cancer as a blessing in disguise.

From Olivia Munn opening up about undergoing a hysterectomy and egg retrieval to Michael McDonald’s learned lesson after his wife’s cancer, here’s what’s going on in the oncology space this week.

A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

Ignoring fear and anxiety only allows them to grow until they explode into a full-blown anxiety attack. It’s okay to be scared about cancer progression.

The addition of Tecentriq to chemotherapy did not improve overall survival in patients with relapsed triple-negative breast cancer.

These poems encapsulated my successful battle with stage 4 Hodgkin lymphoma.

The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®.

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

Radiation without chemotherapy was sufficient in treating locally recurrent endometrial cancer, allowing for patients to skip chemo-related side effects.

This poem is a reflection of some of my thoughts and feelings when my wife received a diagnosis of triple-negative breast cancer.

A metastatic breast cancer diagnosis can come as “a shock,” but experts spoke with CURE® about ways patients can navigate their experiences and treatments.

Imfinzi should be standard of care for post-chemoradiotherapy non-small cell lung cancer treatment, but some patients are not getting the drug, a study found.

Putting a focus on healing is most important before fixating on the far future. Take it one day at a time.

Caitlin Fanning, M.S.N., RN, OCN, is an oncology nurse who "focuses on empowerment."

I believe a divine intervention miraculously saved my life when I had a dream about breast cancer — it turned out to be true.

Marie Riehl's willingness to step outside of her professional comfort zone has allowed her to be an extraordinary patient advocate.

“I think there is a very near future where we have available breast cancer vaccines for all of us, our children and for everybody,” said Kristen Dahlgren.

Quitting drinking alcohol was so important for my well-being and also decreases the threat of developing certain cancers, especially with Lynch syndrome.